nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP1A2—Carmustine—lymphatic system cancer	0.176	0.366	CbGbCtD
Irbesartan—CYP2C9—Teniposide—lymphatic system cancer	0.107	0.222	CbGbCtD
Irbesartan—CYP3A4—Cytarabine—lymphatic system cancer	0.0629	0.131	CbGbCtD
Irbesartan—CYP3A4—Teniposide—lymphatic system cancer	0.062	0.129	CbGbCtD
Irbesartan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0433	0.0902	CbGbCtD
Irbesartan—CYP3A4—Vincristine—lymphatic system cancer	0.0298	0.0621	CbGbCtD
Irbesartan—Anaemia—Bleomycin—lymphatic system cancer	0.000955	0.00184	CcSEcCtD
Irbesartan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000948	0.00183	CcSEcCtD
Irbesartan—Asthenia—Teniposide—lymphatic system cancer	0.000939	0.00181	CcSEcCtD
Irbesartan—Malaise—Bleomycin—lymphatic system cancer	0.000932	0.00179	CcSEcCtD
Irbesartan—Pruritus—Teniposide—lymphatic system cancer	0.000926	0.00178	CcSEcCtD
Irbesartan—Arrhythmia—Carmustine—lymphatic system cancer	0.000926	0.00178	CcSEcCtD
Irbesartan—Leukopenia—Bleomycin—lymphatic system cancer	0.000925	0.00178	CcSEcCtD
Irbesartan—Cardiac disorder—Vincristine—lymphatic system cancer	0.000918	0.00177	CcSEcCtD
Irbesartan—Body temperature increased—Fludarabine—lymphatic system cancer	0.000909	0.00175	CcSEcCtD
Irbesartan—Malnutrition—Carmustine—lymphatic system cancer	0.000902	0.00174	CcSEcCtD
Irbesartan—Erythema—Carmustine—lymphatic system cancer	0.000902	0.00174	CcSEcCtD
Irbesartan—Cough—Bleomycin—lymphatic system cancer	0.000902	0.00174	CcSEcCtD
Irbesartan—Angiopathy—Vincristine—lymphatic system cancer	0.000898	0.00173	CcSEcCtD
Irbesartan—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000897	0.00173	CcSEcCtD
Irbesartan—Diarrhoea—Teniposide—lymphatic system cancer	0.000896	0.00172	CcSEcCtD
Irbesartan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000892	0.00172	CcSEcCtD
Irbesartan—Chest pain—Bleomycin—lymphatic system cancer	0.00088	0.00169	CcSEcCtD
Irbesartan—Myalgia—Bleomycin—lymphatic system cancer	0.00088	0.00169	CcSEcCtD
Irbesartan—Discomfort—Bleomycin—lymphatic system cancer	0.000869	0.00167	CcSEcCtD
Irbesartan—Chills—Mitoxantrone—lymphatic system cancer	0.000864	0.00166	CcSEcCtD
Irbesartan—Ecchymosis—Methotrexate—lymphatic system cancer	0.000864	0.00166	CcSEcCtD
Irbesartan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000861	0.00166	CcSEcCtD
Irbesartan—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000851	0.00164	CcSEcCtD
Irbesartan—Vision blurred—Carmustine—lymphatic system cancer	0.00085	0.00164	CcSEcCtD
Irbesartan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000848	0.00163	CcSEcCtD
Irbesartan—Tremor—Carmustine—lymphatic system cancer	0.000845	0.00163	CcSEcCtD
Irbesartan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000843	0.00162	CcSEcCtD
Irbesartan—Oedema—Bleomycin—lymphatic system cancer	0.000843	0.00162	CcSEcCtD
Irbesartan—Erythema—Mitoxantrone—lymphatic system cancer	0.000839	0.00161	CcSEcCtD
Irbesartan—Infection—Bleomycin—lymphatic system cancer	0.000838	0.00161	CcSEcCtD
Irbesartan—Anaemia—Carmustine—lymphatic system cancer	0.000834	0.00161	CcSEcCtD
Irbesartan—Vomiting—Teniposide—lymphatic system cancer	0.000832	0.0016	CcSEcCtD
Irbesartan—Agitation—Carmustine—lymphatic system cancer	0.000829	0.0016	CcSEcCtD
Irbesartan—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000826	0.00159	CcSEcCtD
Irbesartan—Asthenia—Fludarabine—lymphatic system cancer	0.000825	0.00159	CcSEcCtD
Irbesartan—Rash—Teniposide—lymphatic system cancer	0.000825	0.00159	CcSEcCtD
Irbesartan—Dermatitis—Teniposide—lymphatic system cancer	0.000825	0.00159	CcSEcCtD
Irbesartan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000821	0.00158	CcSEcCtD
Irbesartan—Headache—Teniposide—lymphatic system cancer	0.00082	0.00158	CcSEcCtD
Irbesartan—Pruritus—Fludarabine—lymphatic system cancer	0.000814	0.00157	CcSEcCtD
Irbesartan—Leukopenia—Carmustine—lymphatic system cancer	0.000808	0.00155	CcSEcCtD
Irbesartan—Anorexia—Bleomycin—lymphatic system cancer	0.000804	0.00155	CcSEcCtD
Irbesartan—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000798	0.00154	CcSEcCtD
Irbesartan—Anaemia—Vincristine—lymphatic system cancer	0.000796	0.00153	CcSEcCtD
Irbesartan—Agitation—Vincristine—lymphatic system cancer	0.000791	0.00152	CcSEcCtD
Irbesartan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00079	0.00152	CcSEcCtD
Irbesartan—Photosensitivity—Methotrexate—lymphatic system cancer	0.00079	0.00152	CcSEcCtD
Irbesartan—Hypotension—Bleomycin—lymphatic system cancer	0.000788	0.00152	CcSEcCtD
Irbesartan—Diarrhoea—Fludarabine—lymphatic system cancer	0.000787	0.00152	CcSEcCtD
Irbesartan—Hypertension—Carmustine—lymphatic system cancer	0.000779	0.0015	CcSEcCtD
Irbesartan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000778	0.0015	CcSEcCtD
Irbesartan—Nausea—Teniposide—lymphatic system cancer	0.000777	0.0015	CcSEcCtD
Irbesartan—Anaemia—Mitoxantrone—lymphatic system cancer	0.000775	0.00149	CcSEcCtD
Irbesartan—Vertigo—Vincristine—lymphatic system cancer	0.000774	0.00149	CcSEcCtD
Irbesartan—Leukopenia—Vincristine—lymphatic system cancer	0.000771	0.00148	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000768	0.00148	CcSEcCtD
Irbesartan—Myalgia—Carmustine—lymphatic system cancer	0.000768	0.00148	CcSEcCtD
Irbesartan—Chest pain—Carmustine—lymphatic system cancer	0.000768	0.00148	CcSEcCtD
Irbesartan—Anxiety—Carmustine—lymphatic system cancer	0.000765	0.00147	CcSEcCtD
Irbesartan—Paraesthesia—Bleomycin—lymphatic system cancer	0.000757	0.00146	CcSEcCtD
Irbesartan—Malaise—Mitoxantrone—lymphatic system cancer	0.000756	0.00146	CcSEcCtD
Irbesartan—Dyspnoea—Bleomycin—lymphatic system cancer	0.000752	0.00145	CcSEcCtD
Irbesartan—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000751	0.00145	CcSEcCtD
Irbesartan—Hypertension—Vincristine—lymphatic system cancer	0.000744	0.00143	CcSEcCtD
Irbesartan—Oedema—Carmustine—lymphatic system cancer	0.000736	0.00142	CcSEcCtD
Irbesartan—Decreased appetite—Bleomycin—lymphatic system cancer	0.000733	0.00141	CcSEcCtD
Irbesartan—Myalgia—Vincristine—lymphatic system cancer	0.000733	0.00141	CcSEcCtD
Irbesartan—Visual disturbance—Methotrexate—lymphatic system cancer	0.000732	0.00141	CcSEcCtD
Irbesartan—Cough—Mitoxantrone—lymphatic system cancer	0.000732	0.00141	CcSEcCtD
Irbesartan—Infection—Carmustine—lymphatic system cancer	0.000731	0.00141	CcSEcCtD
Irbesartan—Vomiting—Fludarabine—lymphatic system cancer	0.000731	0.00141	CcSEcCtD
Irbesartan—Rash—Fludarabine—lymphatic system cancer	0.000725	0.0014	CcSEcCtD
Irbesartan—Dermatitis—Fludarabine—lymphatic system cancer	0.000725	0.0014	CcSEcCtD
Irbesartan—Hypertension—Mitoxantrone—lymphatic system cancer	0.000724	0.00139	CcSEcCtD
Irbesartan—Pain—Bleomycin—lymphatic system cancer	0.000721	0.00139	CcSEcCtD
Irbesartan—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000721	0.00139	CcSEcCtD
Irbesartan—Headache—Fludarabine—lymphatic system cancer	0.000721	0.00139	CcSEcCtD
Irbesartan—Tachycardia—Carmustine—lymphatic system cancer	0.000719	0.00138	CcSEcCtD
Irbesartan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000714	0.00137	CcSEcCtD
Irbesartan—Chest pain—Mitoxantrone—lymphatic system cancer	0.000714	0.00137	CcSEcCtD
Irbesartan—Myalgia—Mitoxantrone—lymphatic system cancer	0.000714	0.00137	CcSEcCtD
Irbesartan—Anxiety—Mitoxantrone—lymphatic system cancer	0.000712	0.00137	CcSEcCtD
Irbesartan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000708	0.00136	CcSEcCtD
Irbesartan—Discomfort—Mitoxantrone—lymphatic system cancer	0.000705	0.00136	CcSEcCtD
Irbesartan—Oedema—Vincristine—lymphatic system cancer	0.000703	0.00135	CcSEcCtD
Irbesartan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000703	0.00135	CcSEcCtD
Irbesartan—Anorexia—Carmustine—lymphatic system cancer	0.000702	0.00135	CcSEcCtD
Irbesartan—Infection—Vincristine—lymphatic system cancer	0.000698	0.00134	CcSEcCtD
Irbesartan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000695	0.00134	CcSEcCtD
Irbesartan—Nervous system disorder—Vincristine—lymphatic system cancer	0.000689	0.00133	CcSEcCtD
Irbesartan—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000688	0.00133	CcSEcCtD
Irbesartan—Hypotension—Carmustine—lymphatic system cancer	0.000688	0.00132	CcSEcCtD
Irbesartan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000684	0.00132	CcSEcCtD
Irbesartan—Oedema—Mitoxantrone—lymphatic system cancer	0.000684	0.00132	CcSEcCtD
Irbesartan—Nausea—Fludarabine—lymphatic system cancer	0.000683	0.00132	CcSEcCtD
Irbesartan—Infection—Mitoxantrone—lymphatic system cancer	0.00068	0.00131	CcSEcCtD
Irbesartan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000679	0.00131	CcSEcCtD
Irbesartan—Shock—Mitoxantrone—lymphatic system cancer	0.000673	0.0013	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000671	0.00129	CcSEcCtD
Irbesartan—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00067	0.00129	CcSEcCtD
Irbesartan—Urticaria—Bleomycin—lymphatic system cancer	0.00067	0.00129	CcSEcCtD
Irbesartan—Anorexia—Vincristine—lymphatic system cancer	0.00067	0.00129	CcSEcCtD
Irbesartan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000668	0.00129	CcSEcCtD
Irbesartan—Body temperature increased—Bleomycin—lymphatic system cancer	0.000667	0.00128	CcSEcCtD
Irbesartan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000665	0.00128	CcSEcCtD
Irbesartan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000662	0.00127	CcSEcCtD
Irbesartan—Paraesthesia—Carmustine—lymphatic system cancer	0.000661	0.00127	CcSEcCtD
Irbesartan—Mood swings—Methotrexate—lymphatic system cancer	0.000657	0.00127	CcSEcCtD
Irbesartan—Hypotension—Vincristine—lymphatic system cancer	0.000657	0.00126	CcSEcCtD
Irbesartan—Dyspnoea—Carmustine—lymphatic system cancer	0.000656	0.00126	CcSEcCtD
Irbesartan—Somnolence—Carmustine—lymphatic system cancer	0.000655	0.00126	CcSEcCtD
Irbesartan—Anorexia—Mitoxantrone—lymphatic system cancer	0.000652	0.00126	CcSEcCtD
Irbesartan—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000641	0.00123	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00064	0.00123	CcSEcCtD
Irbesartan—Decreased appetite—Carmustine—lymphatic system cancer	0.00064	0.00123	CcSEcCtD
Irbesartan—Hypotension—Mitoxantrone—lymphatic system cancer	0.00064	0.00123	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000636	0.00122	CcSEcCtD
Irbesartan—Paraesthesia—Vincristine—lymphatic system cancer	0.000631	0.00122	CcSEcCtD
Irbesartan—Pain—Carmustine—lymphatic system cancer	0.00063	0.00121	CcSEcCtD
Irbesartan—Constipation—Carmustine—lymphatic system cancer	0.00063	0.00121	CcSEcCtD
Irbesartan—Breast disorder—Methotrexate—lymphatic system cancer	0.000627	0.00121	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000625	0.0012	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000624	0.0012	CcSEcCtD
Irbesartan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000621	0.0012	CcSEcCtD
Irbesartan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000615	0.00118	CcSEcCtD
Irbesartan—Decreased appetite—Vincristine—lymphatic system cancer	0.000611	0.00118	CcSEcCtD
Irbesartan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00061	0.00118	CcSEcCtD
Irbesartan—Somnolence—Mitoxantrone—lymphatic system cancer	0.000609	0.00117	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000607	0.00117	CcSEcCtD
Irbesartan—Feeling abnormal—Carmustine—lymphatic system cancer	0.000607	0.00117	CcSEcCtD
Irbesartan—Fatigue—Vincristine—lymphatic system cancer	0.000606	0.00117	CcSEcCtD
Irbesartan—Asthenia—Bleomycin—lymphatic system cancer	0.000605	0.00117	CcSEcCtD
Irbesartan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000603	0.00116	CcSEcCtD
Irbesartan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000602	0.00116	CcSEcCtD
Irbesartan—Constipation—Vincristine—lymphatic system cancer	0.000601	0.00116	CcSEcCtD
Irbesartan—Pain—Vincristine—lymphatic system cancer	0.000601	0.00116	CcSEcCtD
Irbesartan—Asthma—Methotrexate—lymphatic system cancer	0.0006	0.00115	CcSEcCtD
Irbesartan—Pruritus—Bleomycin—lymphatic system cancer	0.000597	0.00115	CcSEcCtD
Irbesartan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000595	0.00115	CcSEcCtD
Irbesartan—Fatigue—Mitoxantrone—lymphatic system cancer	0.00059	0.00114	CcSEcCtD
Irbesartan—Pancreatitis—Methotrexate—lymphatic system cancer	0.000588	0.00113	CcSEcCtD
Irbesartan—Pain—Mitoxantrone—lymphatic system cancer	0.000585	0.00113	CcSEcCtD
Irbesartan—Constipation—Mitoxantrone—lymphatic system cancer	0.000585	0.00113	CcSEcCtD
Irbesartan—Abdominal pain—Carmustine—lymphatic system cancer	0.000582	0.00112	CcSEcCtD
Irbesartan—Body temperature increased—Carmustine—lymphatic system cancer	0.000582	0.00112	CcSEcCtD
Irbesartan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000575	0.00111	CcSEcCtD
Irbesartan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000564	0.00109	CcSEcCtD
Irbesartan—Neutropenia—Methotrexate—lymphatic system cancer	0.000561	0.00108	CcSEcCtD
Irbesartan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00056	0.00108	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000557	0.00107	CcSEcCtD
Irbesartan—Body temperature increased—Vincristine—lymphatic system cancer	0.000556	0.00107	CcSEcCtD
Irbesartan—Abdominal pain—Vincristine—lymphatic system cancer	0.000556	0.00107	CcSEcCtD
Irbesartan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000547	0.00105	CcSEcCtD
Irbesartan—Urticaria—Mitoxantrone—lymphatic system cancer	0.000544	0.00105	CcSEcCtD
Irbesartan—Hypersensitivity—Carmustine—lymphatic system cancer	0.000542	0.00104	CcSEcCtD
Irbesartan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000541	0.00104	CcSEcCtD
Irbesartan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000541	0.00104	CcSEcCtD
Irbesartan—Pneumonia—Methotrexate—lymphatic system cancer	0.000538	0.00104	CcSEcCtD
Irbesartan—Vomiting—Bleomycin—lymphatic system cancer	0.000536	0.00103	CcSEcCtD
Irbesartan—Rash—Bleomycin—lymphatic system cancer	0.000532	0.00102	CcSEcCtD
Irbesartan—Dermatitis—Bleomycin—lymphatic system cancer	0.000531	0.00102	CcSEcCtD
Irbesartan—Asthenia—Carmustine—lymphatic system cancer	0.000528	0.00102	CcSEcCtD
Irbesartan—Renal failure—Methotrexate—lymphatic system cancer	0.000526	0.00101	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00052	0.001	CcSEcCtD
Irbesartan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000518	0.000997	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000506	0.000974	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—lymphatic system cancer	0.000504	0.000971	CcSEcCtD
Irbesartan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000504	0.000971	CcSEcCtD
Irbesartan—Asthenia—Vincristine—lymphatic system cancer	0.000504	0.000971	CcSEcCtD
Irbesartan—Diarrhoea—Carmustine—lymphatic system cancer	0.000504	0.00097	CcSEcCtD
Irbesartan—Nausea—Bleomycin—lymphatic system cancer	0.000501	0.000965	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000499	0.000961	CcSEcCtD
Irbesartan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000491	0.000946	CcSEcCtD
Irbesartan—Dizziness—Carmustine—lymphatic system cancer	0.000487	0.000937	CcSEcCtD
Irbesartan—Diarrhoea—Vincristine—lymphatic system cancer	0.000481	0.000926	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—lymphatic system cancer	0.00048	0.000924	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—lymphatic system cancer	0.000476	0.000917	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000474	0.000913	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000471	0.000906	CcSEcCtD
Irbesartan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000468	0.000902	CcSEcCtD
Irbesartan—Vomiting—Carmustine—lymphatic system cancer	0.000468	0.000901	CcSEcCtD
Irbesartan—Dizziness—Vincristine—lymphatic system cancer	0.000465	0.000895	CcSEcCtD
Irbesartan—Rash—Carmustine—lymphatic system cancer	0.000464	0.000894	CcSEcCtD
Irbesartan—Dermatitis—Carmustine—lymphatic system cancer	0.000464	0.000893	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—lymphatic system cancer	0.000463	0.000891	CcSEcCtD
Irbesartan—Headache—Carmustine—lymphatic system cancer	0.000461	0.000888	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—lymphatic system cancer	0.000448	0.000862	CcSEcCtD
Irbesartan—Vomiting—Vincristine—lymphatic system cancer	0.000447	0.00086	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000445	0.000858	CcSEcCtD
Irbesartan—Rash—Vincristine—lymphatic system cancer	0.000443	0.000853	CcSEcCtD
Irbesartan—Dermatitis—Vincristine—lymphatic system cancer	0.000443	0.000853	CcSEcCtD
Irbesartan—Headache—Vincristine—lymphatic system cancer	0.00044	0.000848	CcSEcCtD
Irbesartan—Nausea—Carmustine—lymphatic system cancer	0.000437	0.000842	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—lymphatic system cancer	0.000436	0.000839	CcSEcCtD
Irbesartan—Vomiting—Mitoxantrone—lymphatic system cancer	0.000435	0.000838	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000434	0.000835	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000433	0.000833	CcSEcCtD
Irbesartan—Rash—Mitoxantrone—lymphatic system cancer	0.000432	0.000831	CcSEcCtD
Irbesartan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000431	0.00083	CcSEcCtD
Irbesartan—Chills—Methotrexate—lymphatic system cancer	0.000431	0.000829	CcSEcCtD
Irbesartan—Headache—Mitoxantrone—lymphatic system cancer	0.000429	0.000826	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—lymphatic system cancer	0.000418	0.000805	CcSEcCtD
Irbesartan—Erythema—Methotrexate—lymphatic system cancer	0.000418	0.000805	CcSEcCtD
Irbesartan—Nausea—Vincristine—lymphatic system cancer	0.000417	0.000804	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000409	0.000788	CcSEcCtD
Irbesartan—Nausea—Mitoxantrone—lymphatic system cancer	0.000407	0.000783	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—lymphatic system cancer	0.000394	0.000758	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000388	0.000747	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—lymphatic system cancer	0.000386	0.000744	CcSEcCtD
Irbesartan—Malaise—Methotrexate—lymphatic system cancer	0.000377	0.000726	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—lymphatic system cancer	0.000375	0.000723	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—lymphatic system cancer	0.000374	0.00072	CcSEcCtD
Irbesartan—Cough—Methotrexate—lymphatic system cancer	0.000365	0.000702	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—lymphatic system cancer	0.000356	0.000685	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—lymphatic system cancer	0.000356	0.000685	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—lymphatic system cancer	0.000356	0.000685	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000353	0.00068	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—lymphatic system cancer	0.000351	0.000677	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000341	0.000657	CcSEcCtD
Irbesartan—Infection—Methotrexate—lymphatic system cancer	0.000339	0.000652	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000334	0.000644	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000334	0.000643	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—lymphatic system cancer	0.000331	0.000638	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00033	0.000635	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—lymphatic system cancer	0.000325	0.000626	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—lymphatic system cancer	0.000319	0.000614	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000311	0.000598	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000306	0.00059	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000304	0.000585	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—lymphatic system cancer	0.000303	0.000584	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—lymphatic system cancer	0.0003	0.000578	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000296	0.000571	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000294	0.000567	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—lymphatic system cancer	0.000294	0.000566	CcSEcCtD
Irbesartan—Pain—Methotrexate—lymphatic system cancer	0.000292	0.000562	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000281	0.000541	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000279	0.000537	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—lymphatic system cancer	0.000271	0.000522	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—lymphatic system cancer	0.00027	0.000519	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—lymphatic system cancer	0.00027	0.000519	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000251	0.000484	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—lymphatic system cancer	0.000245	0.000471	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—lymphatic system cancer	0.000241	0.000465	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000233	0.000449	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—lymphatic system cancer	0.000226	0.000434	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—lymphatic system cancer	0.000217	0.000418	CcSEcCtD
Irbesartan—Rash—Methotrexate—lymphatic system cancer	0.000215	0.000414	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—lymphatic system cancer	0.000215	0.000414	CcSEcCtD
Irbesartan—Headache—Methotrexate—lymphatic system cancer	0.000214	0.000411	CcSEcCtD
Irbesartan—Nausea—Methotrexate—lymphatic system cancer	0.000203	0.00039	CcSEcCtD
